AI Portfolio Summary
In 2025 Q4, SECTORAL ASSET MANAGEMENT INC maintained a portfolio of 88 distinct positions. The most significant new addition to the portfolio was EVOMMUNE INC, which now represents 8.08% of the total fund value. Conversely, SECTORAL ASSET MANAGEMENT INC completely exited their position in ANAPTYSBIO INC.
Total Positions
88
Quarter
2025 Q4
Top Holding
EVMN (8.1%)
Top 10 Concentration
46.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 88
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EVMN
EVOMMUNE INC
|
Healthcare | 8.08% | — |
#1
Prev: #—
|
8.7 | 589,005 | no change |
NEW
|
589,005 | $10,083,766 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CTNM
CONTINEUM THERA...
|
Healthcare | 7.34% | 5.81% |
#2
1
Prev: #1
|
5.4 | no change | no change |
P
S
|
800,787 | $9,152,995 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LLY
ELI LILLY & CO
|
Healthcare | 6.27% | 4.42% |
#3
1
Prev: #2
|
3.5 | -2,100 | -22.4% |
P
S
|
7,276 | $7,819,372 | 2005 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SI
SHOULDER INNOVA...
|
Unknown | 5.64% | 3.33% |
#4
1
Prev: #5
|
4.8 | 62,153 | 14.4% |
P
S
|
492,435 | $7,041,821 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UNH
UNITEDHEALTH GR...
|
Healthcare | 3.60% | 2.89% |
#5
3
Prev: #8
|
2.4 | 50 | 0.4% |
P
S
|
13,595 | $4,487,845 | 2003 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMGN
AMGEN INC
|
Healthcare | 3.43% | 1.80% |
#6
15
Prev: #21
|
3.9 | 2,730 | 26.4% |
P
S
|
13,070 | $4,277,942 | 2004 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JNJ
JOHNSON & JOHNS...
|
Healthcare | 3.37% | 1.75% |
#7
17
Prev: #24
|
3.8 | 5,000 | 32.7% |
P
S
|
20,300 | $4,201,085 | 2009 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABBV
ABBVIE INC
|
Healthcare | 3.08% | 2.12% |
#8
6
Prev: #14
|
3.2 | 2,000 | 13.5% |
P
S
|
16,800 | $3,838,632 | 2013 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRTX
VERTEX PHARMA
|
Healthcare | 2.91% | 1.86% |
#9
11
Prev: #20
|
1.7 | 290 | 3.8% |
P
S
|
8,005 | $3,629,147 | 2004 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABT
ABBOTT LABS
|
Healthcare | 2.36% | 1.42% |
#10
17
Prev: #27
|
3.4 | 6,300 | 36.6% |
P
S
|
23,498 | $2,944,064 | 2008 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
REGN
REGENERON PHARM...
|
Healthcare | 2.30% | 1.38% |
#11
17
Prev: #28
|
1.4 | -253 | -6.4% |
P
S
|
3,715 | $2,867,497 | 2012 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ISRG
INTUITIVE SURGI...
|
Healthcare | 2.20% | 1.59% |
#12
13
Prev: #25
|
1.4 | -900 | -15.7% |
P
S
|
4,850 | $2,746,846 | 2007 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BSX
BOSTON SCIENTIF...
|
Healthcare | 2.11% | 1.33% |
#13
17
Prev: #30
|
3.3 | 5,500 | 24.9% |
P
S
|
27,626 | $2,634,139 | 2003 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARGX
ARGENX SE SPN A...
|
Healthcare | 1.95% | 1.77% |
#14
9
Prev: #23
|
0.8 | -996 | -25.6% |
P
S
|
2,894 | $2,433,710 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DHR
DANAHER CORP
|
Healthcare | 1.94% | 1.30% |
#15
16
Prev: #31
|
1.8 | no change | no change |
P
S
|
10,575 | $2,420,829 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYK
STRYKER CORP
|
Healthcare | 1.85% | 0.98% |
#16
21
Prev: #37
|
3.7 | 2,250 | 52.3% |
P
S
|
6,550 | $2,302,129 | 2008 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TMO
THERMO FISHER S...
|
Healthcare | 1.81% | 1.17% |
#17
17
Prev: #34
|
1.7 | no change | no change |
P
S
|
3,900 | $2,259,855 | 2010 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRK
MERCK & CO INC
|
Healthcare | 1.81% | 0.86% |
#18
24
Prev: #42
|
3.2 | 5,000 | 30.5% |
P
S
|
21,400 | $2,252,564 | 2008 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GILD
GILEAD SCIENCES...
|
Healthcare | 1.76% | 1.34% |
#19
10
Prev: #29
|
1.2 | -1,665 | -8.5% |
P
S
|
17,885 | $2,195,205 | 2003 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSM
INSMED INC
|
Healthcare | 1.56% | 1.19% |
#20
13
Prev: #33
|
1.1 | -2,243 | -16.7% |
P
S
|
11,182 | $1,946,115 | 2013 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DXCM
DEXCOM INC
|
Healthcare | 1.53% | 0.86% |
#21
20
Prev: #41
|
3.1 | 8,000 | 38.6% |
P
S
|
28,700 | $1,904,819 | 2008 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 1.50% | 0.54% |
#22
32
Prev: #54
|
3.1 | 6,670 | 22.1% |
P
S
|
36,858 | $1,866,490 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 1.33% | 3.83% |
#23
20
Prev: #3
|
0.5 | -198,000 | -89.2% |
P
S
|
23,872 | $1,660,298 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BNTX
BIONTECH SE
|
Healthcare | 1.31% | 1.07% |
#24
12
Prev: #36
|
1.0 | -442 | -2.5% |
P
S
|
17,218 | $1,639,154 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EW
EDWARDS LIFESCI...
|
Healthcare | 1.18% | 0.72% |
#25
22
Prev: #47
|
2.5 | 2,250 | 15.0% |
P
S
|
17,250 | $1,470,563 | 2010 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ANAB
ANAPTYSBIO INC
|
Healthcare | 0.00% | 3.68% |
Sold All 😨
(Was: #4) |
0.0 | -194,485 | -100.0% |
CLOSED
|
— | $— | 2018 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCAX
BICARA THERAPEU...
|
Healthcare | 0.00% | 2.60% |
Sold All 😨
(Was: #9) |
0.0 | -266,495 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLDB
SOLID BIOSCIENC...
|
Healthcare | 0.00% | 2.41% |
Sold All 😨
(Was: #11) |
0.0 | -633,052 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 0.00% | 2.11% |
Sold All 😨
(Was: #15) |
0.0 | -194,898 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XBI
SPDR SERIES TRU...
|
Unknown | 0.00% | 2.10% |
Sold All 😨
(Was: #16) |
0.0 | -34,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZBIO
ZENAS BIOPHARMA
|
Healthcare | 0.00% | 2.08% |
Sold All 😨
(Was: #17) |
0.0 | -152,025 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PVLA
PALVELLA THERAP...
|
Healthcare | 0.00% | 1.90% |
Sold All 😨
(Was: #18) |
0.0 | -49,115 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TIL
INSTIL BIO INC
|
Healthcare | 0.00% | 1.78% |
Sold All 😨
(Was: #22) |
0.0 | -161,380 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRUS
MERUS B V
|
Healthcare | 0.00% | 0.67% |
Sold All 😨
(Was: #49) |
0.0 | -11,545 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CI
THE CIGNA GROUP
|
Healthcare | 0.00% | 0.32% |
Sold All 😨
(Was: #67) |
0.0 | -1,800 | -100.0% |
CLOSED
|
— | $— | 2010 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMY
BRISTOL MYERS S...
|
Healthcare | 0.00% | 0.30% |
Sold All 😨
(Was: #68) |
0.0 | -10,800 | -100.0% |
CLOSED
|
— | $— | 2003 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZLAB
ZAI LAB LTD
|
Healthcare | 0.00% | 0.26% |
Sold All 😨
(Was: #69) |
0.0 | -12,590 | -100.0% |
CLOSED
|
— | $— | 2017 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 0.00% | 0.09% |
Sold All 😨
(Was: #79) |
0.0 | -4,205 | -100.0% |
CLOSED
|
— | $— | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 0.00% | 0.00% |
Sold All 😨
(Was: #82) |
0.0 | -956 | -100.0% |
CLOSED
|
— | $— | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 88 holdings